{"document": {"publication": "Tag My News", "full_text": "exelixis inc's cabozantinib experimental drug shrank bone malignancies from prostate cancer in 76 percent of patients, interim results from a midstage trial show.", "title": "exelixis drug slows prostate cancer spread in trial", "line_count": 1, "filename": "5934", "publication_date": "06-06-2011 23:42:03", "lines_and_colors": [["exelixis inc's cabozantinib experimental drug shrank bone malignancies from prostate cancer in 76 percent of patients, interim results from a midstage trial show.", {}]]}}